Nasdaq · CIK 0001842952
CNTX Context Therapeutics Inc.
Insider trading from SEC Form 4. Last filing Jun 12, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
11
with a Form 4 at this company
Signals
Open-market buys and sells at Context Therapeutics Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 52Moderate | Jennifer Lynn Minai-Azary Chief Financial Officer buy | $25k 40,010 shares | +100% | - | |
| 40Moderate | Alex C. Levit Chief Legal Officer, Corp. Sec buy | $12k 20,000 shares | +222% | - | |
| 51Moderate | Martin A. Lehr Chief Executive Officer buy | $70k 100,000 shares | +12% | - |
Transactions
The last 15 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 12, 2025 | Linda West director | AGrant or award Stock Option (right to buy)derivative | +123,500 | $0.00 | $0 | 123,500 | Jun 12, 2025 |
| Jun 12, 2025 | Luke Nathaniel Walker director | AGrant or award Stock Option (right to buy)derivative | +123,500 | $0.00 | $0 | 123,500 | Jun 12, 2025 |
| Jun 12, 2025 | Jennifer Evans Stacey director | AGrant or award Stock Option (right to buy)derivative | +123,500 | $0.00 | $0 | 123,500 | Jun 12, 2025 |
| Jun 12, 2025 | Karen L. Smith director | AGrant or award Stock Option (right to buy)derivative | +123,500 | $0.00 | $0 | 123,500 | Jun 12, 2025 |
| Jun 12, 2025 | Philip W. Kantoff director | AGrant or award Stock Option (right to buy)derivative | +123,500 | $0.00 | $0 | 123,500 | Jun 12, 2025 |
| Jun 12, 2025 | Andy Pasternak director | AGrant or award Stock Option (right to buy)derivative | +138,900 | $0.00 | $0 | 138,900 | Jun 12, 2025 |
| Jun 9, 2025 | Martin A. Lehr Chief Executive Officer | POpen-market purchase Common Stockindirect: Martin Lehr 2000 Trust | +100,000 | $0.70 | $70k | 920,190 | Jun 10, 2025 |
| Jun 6, 2025 | Jennifer Lynn Minai-Azary Chief Financial Officer | POpen-market purchase Common Stock | +40,010 | $0.64 | $25k | 80,010 | Jun 10, 2025 |
| Jun 6, 2025 | Alex C. Levit Chief Legal Officer, Corp. Sec | POpen-market purchase Common Stock | +20,000 | $0.58 | $12k | 29,000 | Jun 10, 2025 |
| Jun 9, 2025 | Karen Deborah Chagin Chief Medical Officer | AGrant or award Stock Option (right to buy)derivative | +153,000 | $0.00 | $0 | 153,000 | Jun 9, 2025 |
| Feb 13, 2025 | Martin A. Lehr Chief Executive Officer | AGrant or award Stock Option (right to buy)derivative | +802,700 | $0.00 | $0 | 802,700 | Feb 14, 2025 |
| Feb 13, 2025 | Ullmann Claudio Dansky Chief Medical Officer | AGrant or award Stock Option (right to buy)derivative | +174,960 | $0.00 | $0 | 174,960 | Feb 14, 2025 |
| Feb 13, 2025 | Alex C. Levit Chief Legal Officer, Corp. Sec | AGrant or award Stock Option (right to buy)derivative | +349,900 | $0.00 | $0 | 349,900 | Feb 14, 2025 |
| Feb 13, 2025 | Jennifer Lynn Minai-Azary Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | +371,800 | $0.00 | $0 | 371,800 | Feb 14, 2025 |
| Jan 13, 2025 | Andy Pasternak director | AGrant or award Stock Option (right to buy)derivative | +20,685 | $0.00 | $0 | 20,685 | Jan 14, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Karen Deborah ChaginChief Medical Officer
- Ullmann Claudio DanskyChief Medical Officer
- Philip W. Kantoffdirector
- Martin A. LehrChief Executive Officer
- Alex C. LevitChief Legal Officer, Corp. Sec
- Jennifer Lynn Minai-AzaryChief Financial Officer
- Andy Pasternakdirector
- Karen L. Smithdirector
- Jennifer Evans Staceydirector
- Luke Nathaniel Walkerdirector
- Linda Westdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.